Brief Report: Linking Depressive Symptoms to Viral Nonsuppression Among Women With HIV Through Adherence Self-Efficacy and ART Adherence.
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Author
Crockett, Kaylee BEntler, Kristin J
Brodie, Emilee
Kempf, Mirjam-Colette
Konkle-Parker, Deborah
Wilson, Tracey E
Tien, Phyllis C
Wingood, Gina
Neilands, Torsten B
Johnson, Mallory O
Weiser, Sheri D
Turan, Janet M
Turan, Bulent
Journal title
Journal of acquired immune deficiency syndromes (1999)Date Published
2020-04Publication Volume
83Publication Issue
4Publication Begin page
340Publication End page
344
Metadata
Show full item recordAbstract
Background: Depression plays a key role in suboptimal HIV outcomes, possibly mediated by adherence self-efficacy beliefs and antiretroviral treatment (ART) adherence behavior. Applying social-cognitive theory, we examined a longitudinal sequential path model of the association between depressive symptoms and viral nonsuppression in women with HIV (WWH) through these mediating mechanisms.Methods: This was an observational longitudinal study using data from the Women's Adherence and Visit Engagement substudy of the Women's Interagency HIV Study. WWH (N = 375) completed measures of depressive symptoms, adherence self-efficacy, and ART adherence. Viral load was measured through blood draw. We examined a longitudinal sequential path model spanning 3 time points at least 6 months apart between 2015 and 2017. Indirect effects were assessed of depressive symptoms at time 1 (T1) on viral nonsuppression at T3 through adherence self-efficacy at T2 and ART adherence at T3. Covariates included age, income, recreational drug use, race, and months on ART.
Results: Depressive symptoms were associated with subsequent viral nonsuppression through its association with adherence self-efficacy and ART adherence [indirect effect: adjusted odds ratio = 1.004, 95% confidence interval: (1.001 to 1.008)]. Months on ART and recreational drug use were also significantly associated with viral nonsuppression at T3.
Conclusions: Our findings support depressive symptoms' association with adherence self-efficacy that in turn lead to suboptimal ART adherence and ultimately to viral nonsuppression for WWH. Tailoring of interventions aimed at addressing depressive symptoms, substance use, and adherence self-efficacy among WWH is needed to help close the gap between ART prescription and viral suppression on the HIV care continuum.
Citation
Crockett KB, Entler KJ, Brodie E, Kempf MC, Konkle-Parker D, Wilson TE, Tien PC, Wingood G, Neilands TB, Johnson MO, Weiser SD, Turan JM, Turan B. Brief Report: Linking Depressive Symptoms to Viral Nonsuppression Among Women With HIV Through Adherence Self-Efficacy and ART Adherence. J Acquir Immune Defic Syndr. 2020 Apr 1;83(4):340-344. doi: 10.1097/QAI.0000000000002268. PMID: 32097193; PMCID: PMC7266092.DOI
10.1097/QAI.0000000000002268ae974a485f413a2113503eed53cd6c53
10.1097/QAI.0000000000002268
Scopus Count
Collections
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International
Related articles
- Plasma Viral Load of 200 Copies/mL is a Suitable Threshold to Define Viral Suppression and HIV Drug Resistance Testing in Low- and Middle-Income Countries: Evidence From a Facility-Based Study in Cameroon.
- Authors: Chenwi CA, Nayang Mundo RA, Nka AD, Semengue ENJ, Beloumou GA, Ka'e AC, Togna Pabo WL, Takou D, Abba A, Djupsa SC, Molimbou E, Etame NK, Kengni Ngueko AM, Same DK, Bouba Pamen JN, Abah Abah AS, Billong SC, Ajeh Awoh R, Halle-Ekane GE, Cappelli G, Njom-Nlend AE, Zk Bissek AC, Temfack E, Santoro MM, Ceccherini-Silberstein F, Colizzi V, Kaseya J, Ndembi N, Ndjolo A, Perno CF, Fokam J
- Issue date: 2024 Jan-Dec
- HIV care cascade and associated factors among men who have sex with men, transgender women, and genderqueer individuals in Zimbabwe: findings from a biobehavioural survey using respondent-driven sampling.
- Authors: Harris TG, Wu Y, Parmley LE, Musuka G, Mapingure MP, Chingombe I, Mugurungi O, Hakim A, Gozhora P, Miller SS, Lamb MR, Samba C, Rogers JH
- Issue date: 2022 Mar
- Positive STEPS: Enhancing Medication Adherence and Achieving Viral Load Suppression in Youth Living with HIV in the United States - Results from a Stepped-Care Randomized Controlled Efficacy Trial.
- Authors: Mimiaga MJ, Kuhns LM, Biello KB, Tian J, Skeer MR, Psaros C, Moitra E, Chen D, Yonko E, Mayer KH, Safren SA, Garofalo R
- Issue date: 2025 Jan 30
- Implementation and outcomes of dolutegravir-based first-line antiretroviral therapy for people with HIV in South Africa: a retrospective cohort study.
- Authors: Dorward J, Sookrajh Y, Khubone T, van der Molen J, Govender R, Phakathi S, Lewis L, Bottomley C, Maraj M, Lessells RJ, Naidoo K, Butler CC, Van Heerden R, Garrett N
- Issue date: 2023 May
- Internalized HIV stigma and viral suppression: examining the mediating and moderating roles of substance use and social support.
- Authors: Crawford TN, Neilands TB, Drumright LN, Fredericksen RJ, Johnson MO, Mayer KH, Bamford L, Batchelder AW, Crane HM, Elopre L, Moore RD, Rosengren AL, Christopoulos KA
- Issue date: 2024 Dec 1